Research programme: amyotrophic lateral sclerosis gene therapy - Ceregene/Salk Institute
Alternative Names: AAV-IGF-1; ALS gene therapy - Ceregene/Salk Institute; CERE-135; IGF-1 gene therapyLatest Information Update: 04 Nov 2017
At a glance
- Originator Salk Institute
- Developer Ceregene
- Class Gene therapies
- Mechanism of Action Gene transference; Insulin-like growth factor I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis